A NEW all-oral, fixed-duration therapy for Chronic Lymphocytic Leukaemia (CLL) and Small Lymphocytic Lymphoma (SLL) has been listed on the PBS.
The combination of Imbruvica (ibrutinib) and venetoclax tablets offers a non-chemo option for newly diagnosed and untreated patients.
Prof Con Tam, Head of Lymphoma Services, Alfred Health, said this 15-month treatment allows around 90% of patients to remain treatment-free for over four years.
The above article was sent to subscribers in Pharmacy Daily's issue from 03 Oct 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Oct 24
